🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 06 Jul 2026 · EMA CTIS official data

Clinical Trials in Spain

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

232
Recent authorisations
100
Phase III trials
Spain
Selected country
Phase I/II Neoplasms Authorised 01/07/2026
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc. · 35 participants
📍 France · Spain
2025-523438-24-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 181 participants
📍 Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG · 19 participants
📍 Belgium · Netherlands · Spain · Germany · Italy
2025-523127-21-00 on CTIS ↗
Phase I/II Neoplasms Authorised 30/06/2026
A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
solid tumor
Krystal Biotech Inc. · 40 participants
📍 France · Spain
2025-522723-98-00 on CTIS ↗
Phase II Neoplasms Authorised 30/06/2026
A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)
metastatic pancreatic adecarcinoma
Theriva Biologics S.L. · 6 participants
📍 Spain
2026-525566-21-00 on CTIS ↗
Phase III Neoplasms Authorised 30/06/2026
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc. · 45 participants
📍 Spain · Belgium · France · Italy · Germany
2025-521971-29-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/06/2026
A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers
Treatment of several inflammatory diseases, including inflammation-related fibrosis and autoinflammatory diseases
Allinky Biopharma S.L. · 42 participants
📍 Spain
2026-525830-49-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 40 participants
📍 Germany · Bulgaria · Belgium · Spain · Greece · Italy · Czechia
2025-524855-30-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 46 participants
📍 Spain · Belgium · France · Germany · Slovakia · Bulgaria · Italy · Greece
2025-523871-44-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 29/06/2026
ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
Obstructive sleep apnea syndrome, Obesity
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre · 345 participants
📍 Spain
2026-525500-10-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)
Non-small Cell Lung Cancer
AstraZeneca AB · 11 participants
📍 Spain · Germany
2025-523599-21-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/06/2026
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
Solid Tumors
Revolution Medicines Inc. · 227 participants
📍 France · Spain · Greece · Germany · Italy · Sweden · Belgium
2025-524623-50-00 on CTIS ↗
Phase III Neoplasms Authorised 26/06/2026
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Pancreatic Ductal Adenocarcinoma
Incyte Corp. · 205 participants
📍 Poland · Italy · Netherlands · Sweden · Denmark · Finland · Spain · France · Belgium · Norway · Austria
2025-525009-18-00 on CTIS ↗
Phase II Disorders of Environmental Origin Authorised 26/06/2026
“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.
IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.
Probelte Pharma S.L. · 30 participants
📍 Spain
2026-525628-13-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/06/2026
A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
Multiple Sclerosis
F. Hoffmann-La Roche AG · 54 participants
📍 Spain · France · Poland · Italy
2025-523726-40-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 23/06/2026
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial
infertility
Santiago Dexeus Font Fundacio Privada · 240 participants
📍 Spain
2025-524761-25-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 23/06/2026
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).
Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement · 41 participants
📍 Poland · Spain · France · Netherlands · Germany
2025-523403-29-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 23/06/2026
USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.
Hypoxemic episodes in patients undergoing gastroscopy, colonoscopy, or oral endoscopic ultrasound under deep sedation with oxygen therapy administration.
Hospital Universitario Rio Hortega · 326 participants
📍 Spain
2026-525766-21-01 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Hereditary Angioedema
Adarx Pharmaceuticals Inc. · 45 participants
📍 Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants
📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc. · 88 participants
📍 Germany · France · Poland · Italy · Spain
2025-524488-18-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/06/2026
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc. · 22 participants
📍 Spain
2025-522587-33-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/06/2026
Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events
Coronary atherosclerosis
Daiichi Sankyo Europe GmbH · 103 participants
📍 Italy · Spain · Germany
2025-524625-41-00 on CTIS ↗
Phase I Neoplasms Authorised 22/06/2026
Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma
Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC · 43 participants
📍 Spain · Romania
2025-525158-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 19/06/2026
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)
Systemic Sclerosis
Celgene Corp. · 33 participants
📍 Spain · Germany · France · Italy
2025-524337-11-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 19/06/2026
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
Type 2 diabetes
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 60 participants
📍 Spain
2025-523374-17-03 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 18/06/2026
Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product
Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc. · 3 participants
📍 Spain · France
2024-514190-21-00 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 18/06/2026
A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.
High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A. · 44 participants
📍 Spain
2026-525897-20-00 on CTIS ↗
Phase III Neoplasms Authorised 18/06/2026
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO
Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma
Fondazione GONO G.I. · 212 participants
📍 Spain · Germany · Italy
2025-524048-36-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/06/2026
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR · 110 participants
📍 Spain · Germany · Italy · Sweden · France · Luxembourg
2024-513496-40-00 on CTIS ↗
Phase I Neoplasms Authorised 17/06/2026
Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer
Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer
Rondo Therapeutics Inc. · 34 participants
📍 Spain
2025-524687-38-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company · 318 participants
📍 Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 17/06/2026
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
Systemic sclerosis
Galderma S.A. · 56 participants
📍 Poland · Italy · Bulgaria · France · Greece · Spain · Croatia
2025-522294-11-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
Solid Tumors
Theras Inc. · 2999997 participants
📍 Spain · Italy · France
2025-524690-16-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 16/06/2026
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Duchenne Muscular Dystrophy
Entrada Therapeutics Inc. · 56 participants
📍 Belgium · Italy · Netherlands · Spain
2025-525124-10-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB · 516 participants
📍 France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands
2024-519787-40-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/06/2026
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)
Metastatic Prostate Cancer
AstraZeneca AB · 45 participants
📍 Belgium · Spain · Poland · Italy · Netherlands
2025-520626-37-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Stage I NSCLC
Merck Sharp & Dohme LLC · 283 participants
📍 Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain
2025-522643-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc. · 228 participants
📍 Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica
Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement · 177 participants
📍 France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 15/06/2026
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)
Swedish Orphan Biovitrum AB (publ) · 69 participants
📍 France · Italy · Spain · Germany
2025-524487-37-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation​
Merck Sharp & Dohme LLC · 88 participants
📍 Italy · Netherlands · France · Germany · Spain · Poland · Greece
2025-522038-29-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
Merck Sharp & Dohme LLC · 109 participants
📍 Greece · Netherlands · Sweden · France · Italy · Spain · Denmark
2025-522267-15-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 210 participants
📍 Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria
2025-523674-16-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 11/06/2026
Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.
Refractory Lupus Nephritis
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz · 10 participants
📍 Spain
2025-522449-23-00 on CTIS ↗
Phase III Otorhinolaryngologic Diseases Authorised 11/06/2026
Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS
chronic suppurative otitis media (CSOM)
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre · 88 participants
📍 Spain
2026-525540-15-00 on CTIS ↗
Phase II Neoplasms Authorised 11/06/2026
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas
Gilead Sciences Inc. · 45 participants
📍 Spain · France
2025-524095-27-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 11/06/2026
Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease
Patients with celiac disease
Venter Pharma S.L. · 42 participants
📍 Spain
2026-525518-70-00 on CTIS ↗
Phase III Neoplasms Authorised 09/06/2026
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
Follicular Lymphoma
Merck Sharp & Dohme LLC · 5 participants
📍 France · Spain
2025-522777-10-00 on CTIS ↗
Phase I/II Neoplasms Authorised 09/06/2026
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc. · 210 participants
📍 Italy · France · Germany · Belgium · Spain · Netherlands
2025-523432-39-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 09/06/2026
Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis
Bronchiectasis
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau · 160 participants
📍 Spain
2025-524454-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)
Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc. · 496 participants
📍 Norway · Czechia · Portugal · Austria · Poland · France · Spain
2025-522176-86-01 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/06/2026
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
Nonsegmental vitiligo
Novartis Pharma AG · 80 participants
📍 Germany · Spain · Netherlands · France · Italy
2025-522301-37-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 08/06/2026
PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)
ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus · 500 participants
📍 Spain
2026-525355-93-00 on CTIS ↗
Phase II Neoplasms Authorised 08/06/2026
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).
Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc. · 94 participants
📍 Spain · Italy · France
2025-523984-39-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 08/06/2026
Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?
Laparoscopic cholecystectomy
Fundacion Biomedica Galicia Sur · 66 participants
📍 Spain
2026-525783-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)
Advanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.
Medica Scientia Innovation Research S.L. · 278 participants
📍 Spain
2025-525144-18-00 on CTIS ↗
Phase III Neoplasms Authorised 08/06/2026
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC · 234 participants
📍 Belgium · Czechia · Germany · Denmark · Greece · Netherlands · Poland · Spain · Austria · Italy · France
2025-522818-23-00 on CTIS ↗
Phase II Therapeutics Authorised 08/06/2026
Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.
Parkinson's disease
Universidad Rey Juan Carlos · 40 participants
📍 Spain
2026-525701-12-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 08/06/2026
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer Inc. · 318 participants
📍 Spain · Germany · Poland · Czechia · Greece · Italy · Bulgaria · France · Hungary
2024-518587-12-00 on CTIS ↗
Phase I Neoplasms Authorised 08/06/2026
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
adenocarcinoma of the colon or rectum
Bayer Consumer Care AG · 49 participants
📍 Finland · Spain · Sweden · Italy · Denmark · Netherlands · Belgium
2025-523648-11-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026
KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.
Novartis Pharma AG · 31 participants
📍 Spain · Italy · France · Denmark · Belgium
2025-523537-26-00 on CTIS ↗
Phase II Virus Diseases Authorised 08/06/2026
Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.
HIV-1 infection
Instituto De Salud Carlos III · 60 participants
📍 Spain
2025-524363-20-01 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 08/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 173 participants
📍 Belgium · Greece · Poland · France · Spain · Bulgaria · Italy · Germany · Austria · Netherlands
2025-523675-39-00 on CTIS ↗
Phase II Behavioral Disciplines and Activities Authorised 08/06/2026
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
alcohol dependence
Hospital Universitario 12 De Octubre · 118 participants
📍 Spain
2023-504439-42-03 on CTIS ↗
Phase III Eye Diseases Authorised 05/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 250 participants
📍 Austria · Slovakia · Portugal · Czechia · Hungary · Spain · France · Denmark · Italy · Croatia
2025-524894-17-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 04/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Narcolepsy Type 2
Alkermes Inc. · 98 participants
📍 Spain · Netherlands · Belgium · Italy · France
2025-523912-35-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 03/06/2026
A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
Amyotrofic Lateral Sclerosis (ALS)
Nura Bio Inc. · 46 participants
📍 Poland · Netherlands · Italy · Spain
2025-523939-18-00 on CTIS ↗
Phase III Eye Diseases Authorised 03/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 130 participants
📍 Spain · Poland · Estonia · Latvia · Germany
2025-524575-22-00 on CTIS ↗
Phase I/II Neoplasms Authorised 02/06/2026
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma Inc. · 180 participants
📍 Spain · Ireland · Italy · France · Romania
2025-523590-42-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 02/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Narcolepsy Type 1
Alkermes Inc. · 75 participants
📍 Italy · France · Netherlands · Spain · Belgium
2025-523911-13-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/06/2026
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
Systemic lupus erythematosus
AstraZeneca AB · 97 participants
📍 Poland · Germany · Italy · France · Spain
2025-523670-17-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG · 42 participants
📍 France · Austria · Poland · Netherlands · Spain · Denmark · Italy · Germany · Hungary
2025-522434-32-00 on CTIS ↗
Phase III Immune System Diseases Authorised 01/06/2026
Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests
Allergy to Lepidoglyphus destructor
Inmunotek S.L. · 70 participants
📍 Spain
2025-523426-40-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 01/06/2026
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
Asthma
Novartis Pharma AG · 68 participants
📍 Poland · France · Slovakia · Spain · Hungary · Germany · Romania
2022-502365-26-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
Hemophilia A
F. Hoffmann-La Roche AG · 124 participants
📍 Hungary · Spain · Ireland · Poland · Austria · Germany · Denmark · Belgium · Netherlands · Italy · France
2025-522435-33-00 on CTIS ↗
Phase II Neoplasms Authorised 01/06/2026
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
Chronic Myeloid Leukemia
Grupo Espanol De Leucemia Mieloide Cronica (GELMC) · 30 participants
📍 Spain
2025-521126-15-00 on CTIS ↗
Phase III Neoplasms Authorised 01/06/2026
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
Treatment-naїve mantle cell lymphoma (MCL)
Innocare Pharma Inc. · 102 participants
📍 Poland · France · Czechia · Spain · Romania
2025-524241-27-00 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency
Chronic granulomatous disease (CGD) caused by p47phox deficiency (p47-CGD)
Somagenetix AG · 4 participants
📍 Germany · Spain
2025-524423-50-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 29/05/2026
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles · 86 participants
📍 Germany · France · Czechia · Netherlands · Spain
2024-516570-30-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/05/2026
C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.
Locally Advanced or Metastatic Urothelial Cancer
Pfizer Inc. · 36 participants
📍 Netherlands · Spain
2025-523523-21-00 on CTIS ↗
Phase III Neoplasms Authorised 29/05/2026
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
Myelofibrosis
Novartis Pharma AG · 173 participants
📍 Belgium · Germany · Austria · Poland · Spain · Italy · Netherlands · Czechia · France
2025-523555-66-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
Cystic fibrosis
Vertex Pharmaceuticals Inc. · 80 participants
📍 Spain · Sweden · Germany · Italy · Belgium · Czechia · Ireland · Portugal · Netherlands · France · Denmark
2025-523400-72-00 on CTIS ↗
Phase II Neoplasms Authorised 28/05/2026
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences Inc. · 34 participants
📍 Bulgaria · France · Spain
2025-523539-20-00 on CTIS ↗
Phase I/II Neoplasms Authorised 28/05/2026
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Merck Sharp & Dohme LLC · 73 participants
📍 Poland · Italy · France · Germany · Spain
2025-523005-15-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/05/2026
A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC
Extensive stage small cell lung cancer
Novartis Pharma AG · 25 participants
📍 Spain · France
2025-523276-23-00 on CTIS ↗
Phase II Immune System Diseases Authorised 27/05/2026
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
moderate to severe rheumatoid arthritis (RA)
F. Hoffmann-La Roche AG · 46 participants
📍 Italy · Spain · Germany · France · Denmark · Poland · Belgium
2025-523579-47-00 on CTIS ↗
Phase III Immune System Diseases Authorised 27/05/2026
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 302 participants
📍 Slovakia · Germany · Denmark · France · Spain · Italy · Netherlands · Belgium · Poland · Sweden · Austria · Czechia · Hungary
2025-521590-13-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 26/05/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
Duchenne muscular dystrophy
Solid Biosciences Inc. · 62 participants
📍 Spain · Netherlands · France · Italy · Belgium · Germany
2025-522949-22-00 on CTIS ↗
Phase I/II Neoplasms Authorised 26/05/2026
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Neoplasm malignant
Merck Sharp & Dohme LLC · 21 participants
📍 France · Spain · Sweden · Germany · Italy · Belgium · Denmark
2025-522339-32-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 26/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
Severe uncontrolled asthma
Generate Biomedicines Inc. · 73 participants
📍 Italy · Slovakia · Spain · Ireland · Belgium · France
2025-524040-35-00 on CTIS ↗
Phase III Immune System Diseases Authorised 25/05/2026
D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation
Allergy to Dermatophagoides pteronyssinus, Allergy to Dermatophagoides farinae
Inmunotek S.L. · 70 participants
📍 Spain
2025-522469-31-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 25/05/2026
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
relapsed/refractory multiple myeloma
C4 Therapeutics Inc. · 43 participants
📍 Italy · France · Spain · Poland
2025-524181-26-00 on CTIS ↗
Phase I Immune System Diseases Authorised 22/05/2026
A study to test single and multiple doses of MER511 given to adults with Graves’ disease
Graves’ disease
Merida Biosciences Inc. · 28 participants
📍 Spain
2025-523823-23-00 on CTIS ↗
Phase III Neoplasms Authorised 22/05/2026
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
Unresectable Stage III non-small cell lung cancer without progression
Bristol-Myers Squibb Services Unlimited Company · 279 participants
📍 France · Ireland · Germany · Greece · Bulgaria · Spain · Netherlands · Italy · Sweden · Romania · Hungary · Belgium · Austria · Poland
2025-523576-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/05/2026
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Orion Corporation · 85 participants
📍 Finland · Denmark · Spain · France
2025-524620-22-00 on CTIS ↗
Phase II Neoplasms Authorised 21/05/2026
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
Eikon Therapeutics Inc. · 115 participants
📍 Germany · Spain · Netherlands · Romania · Greece · Italy
2025-525013-23-00 on CTIS ↗
Phase II Metabolism Authorised 21/05/2026
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
Adult patients with primary mitochondrial disease
Pharming Technologies B.V. · 117 participants
📍 Belgium · Germany · Czechia · Spain · Denmark · Italy · France
2025-524367-20-00 on CTIS ↗
Phase I Neoplasms Authorised 21/05/2026
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
Neoplasms
Glaxosmithkline Research & Development Limited · 52 participants
📍 Spain · Denmark · Finland · France
2025-524165-25-00 on CTIS ↗
Phase II Eye Diseases Authorised 20/05/2026
An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up
Thyroid Eye Disease
Amgen Inc. · 5 participants
📍 Spain · Poland
2025-523280-38-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 20/05/2026
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
Chronic Spontaneous Urticaria
Novartis Pharma AG · 154 participants
📍 Germany · Spain · France · Poland · Bulgaria · Czechia
2025-524078-40-00 on CTIS ↗
Phase III Immune System Diseases Authorised 20/05/2026
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Hidradenitis Suppurativa (HS)
Novartis Pharma AG · 307 participants
📍 Portugal · Greece · Germany · Hungary · France · Spain · Bulgaria · Slovakia · Poland · Czechia · Belgium · Italy
2025-523259-72-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 20/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Duchenne muscular dystrophy
Avidity Biosciences Inc. · 42 participants
📍 Italy · Germany · France · Spain · Belgium · Poland · Netherlands
2025-523087-20-00 on CTIS ↗
Phase II Immune System Diseases Authorised 19/05/2026
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Rheumatoid arthritis
Elevara Medicines Limited · 95 participants
📍 Czechia · Bulgaria · Hungary · Netherlands · Poland · Spain
2025-524005-32-00 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Metastatic hormone-sensitive prostate cancer
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard · 292 participants
📍 Spain · Germany · France · Portugal · Italy
2025-524408-30-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants
📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania
2025-521632-12-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 19/05/2026
PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 66 participants
📍 Portugal · Greece · Italy · Poland · Estonia · Slovakia · Sweden · Denmark · Belgium · Norway · Romania · France · Spain · Germany · Netherlands · Croatia
2025-523425-17-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations
locally advanced or metastatic NSCLC
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 19 participants
📍 Germany · France · Spain
2025-523567-38-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma or ganglioneuroblastoma (nodular or intermixed)
Fundacio Sant Joan De Deu · 22 participants
📍 Spain
2025-524140-35-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Patients With Muscle-Invasive Bladder Cancer
AstraZeneca AB · 60 participants
📍 Italy · Spain · France · Netherlands
2024-519246-75-01 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
Acute myeloid leukemia
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe · 40 participants
📍 Italy · Spain
2025-524308-31-00 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corp. · 292 participants
📍 Poland · France · Denmark · Norway · Spain · Germany · Belgium · Netherlands · Austria · Italy
2025-523735-19-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 18/05/2026
A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative
Male Infertility
Martin-Luther-Universitaet Halle-Wittenberg · 138 participants
📍 Italy · Spain · Germany
2025-525005-20-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 18/05/2026
A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.
​​Exocrine Pancreatic Insufficiency​
Aimmune Nestle Health Science US R&D LLC · 29 participants
📍 Poland · Hungary · Spain · Bulgaria · Italy
2025-521816-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 18/05/2026
Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Blomia tropicalis
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma
Inmunotek S.L. · 120 participants
📍 Spain
2025-522773-12-00 on CTIS ↗
Phase I/II Neoplasms Authorised 18/05/2026
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer
Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 21 participants
📍 Italy · Spain · Romania
2025-524090-16-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene
AbbVie Deutschland GmbH & Co. KG · 29 participants
📍 Spain · France · Denmark
2024-518871-74-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 18/05/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants
📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary
2025-524316-11-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
Novartis Pharma AG · 14 participants
📍 Spain · France · Germany · Poland · Italy · Netherlands
2025-522138-29-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 18/05/2026
A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.
Asthma
Chiesi Farmaceutici S.p.A. · 606 participants
📍 Germany · Romania · Italy · Bulgaria · Poland · Slovakia · Spain · France
2025-524289-56-00 on CTIS ↗
Phase III Neoplasms Authorised 18/05/2026
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 157 participants
📍 Spain · Norway · Germany · Greece · France · Italy · Netherlands
2025-522007-18-00 on CTIS ↗
Phase I Neoplasms Authorised 18/05/2026
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors
advanced refractory solid tumors
Samsung Bioepis Co. Ltd. · 40 participants
📍 Spain
2025-524192-24-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants
📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia
2025-523586-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/05/2026
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Advanced Solid Tumors
Eikon Therapeutics Inc. · 49 participants
📍 France · Spain · Norway · Italy · Germany · Austria · Poland · Finland
2026-525248-13-00 on CTIS ↗
Phase III Immune System Diseases Authorised 14/05/2026
Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Lepidoglyphus destructor.
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma
Inmunotek S.L. · 120 participants
📍 Spain
2025-522771-28-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 14/05/2026
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/refractory primary central nervous system lymphoma
Deciphera Pharmaceuticals Inc. · 74 participants
📍 Czechia · Germany · Italy · Belgium · Spain · Poland · Austria · France
2025-523389-26-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
Quetzal Therapeutics LLC · 89 participants
📍 Germany · Poland · Spain · Romania · Italy · France
2025-524810-28-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
advanced or metastatic extrapulmonary neuroendocrine carcinoma
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 144 participants
📍 Portugal · Spain · Poland · Sweden · Italy · Czechia · France · Netherlands · Finland · Denmark · Austria · Germany · Belgium · Norway
2025-523869-22-00 on CTIS ↗
Phase IV Virus Diseases Authorised 13/05/2026
A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie
Transplant patients with high recurrent Epstein-Barr infection
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 10 participants
📍 Spain
2025-524786-25-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 13/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or Overweight and Type 2 Diabetes
F. Hoffmann-La Roche AG · 551 participants
📍 Germany · Romania · Czechia · Poland · Hungary · France · Spain · Italy
2025-523106-32-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 295 participants
📍 Czechia · Sweden · Poland · Netherlands · Greece · Latvia · Finland · Norway · Belgium · Austria · Portugal · Romania · Italy · Estonia · France · Ireland · Germany · Spain · Bulgaria · Hungary
2025-520565-51-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 12/05/2026
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
Psoriatic Arthritis
Takeda Development Center Americas Inc. · 638 participants
📍 Germany · Belgium · Spain · Czechia · Croatia · Portugal · Poland · Latvia · Bulgaria · France · Estonia · Hungary · Italy
2025-522586-30-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Non-small cell lung cancer (NSCLC), Cervical cancer (CC), Melanoma, Hepatocellular carcinoma (HCC), Ovarian cancer (OC), Squamous cell carcinoma of head and neck
Dualitybio Inc. · 102 participants
📍 Italy · Poland · France · Spain · Germany
2025-523895-22-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 11/05/2026
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)
Huntington’s Disease Gene Expansion Carriers
F. Hoffmann-La Roche AG · 43 participants
📍 Italy · Poland · Denmark · Germany · Portugal · Spain
2025-520631-17-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 11/05/2026
A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)
Dyslipidemia at High to Very High Cardiovascular Risk
A. Menarini International Licensing S.A. · 338 participants
📍 Spain · Poland · Netherlands · Italy · Slovakia · Czechia · Germany
2025-524265-24-00 on CTIS ↗
Phase III Neoplasms Authorised 11/05/2026
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms
Eli Lilly & Co. · 486 participants
📍 Netherlands · Hungary · France · Austria · Poland · Italy · Denmark · Romania · Greece · Norway · Czechia · Belgium · Spain · Ireland · Germany
2025-522255-25-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 11/05/2026
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
Chronic rhinosinusitis with nasal polyps
Sanofi-Aventis Recherche & Developpement · 146 participants
📍 Germany · Netherlands · Portugal · Denmark · Sweden · Finland · France · Spain · Austria · Italy · Hungary · Romania · Belgium · Czechia · Poland
2025-522983-33-00 on CTIS ↗
Phase I Neoplasms Authorised 08/05/2026
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
Advanced Solid Tumors
Daiichi Sankyo Inc. · 24 participants
📍 France · Spain
2025-521173-13-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/05/2026
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies
Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals Inc. · 99 participants
📍 Italy · Spain · Germany · France
2025-523399-22-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/05/2026
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics Inc. · 32 participants
📍 Germany · Spain
2025-523797-17-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 07/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight Without Type 2 Diabetes
F. Hoffmann-La Roche AG · 754 participants
📍 Poland · Hungary · France · Belgium · Italy · Netherlands · Czechia · Germany · Spain
2025-523104-71-00 on CTIS ↗
Phase III Not possible to specify Authorised 07/05/2026
Optimizing Aspirin Use for Preeclampsia Prevention
Obstetrics – Preeclampsia
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 11836 participants
📍 Spain
2025-524646-94-00 on CTIS ↗
Phase II Female Urogenital Diseases and Pregnancy Complications Authorised 06/05/2026
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters
Women with an indication for IVF/ICSI
ReproNovo ApS · 120 participants
📍 Spain
2025-524896-22-00 on CTIS ↗
Phase II Neoplasms Authorised 06/05/2026
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
Non-Small Cell Lung Cancer
AstraZeneca AB · 70 participants
📍 France · Italy · Spain
2025-524843-11-00 on CTIS ↗
Phase I/II Skin and Connective Tissue Diseases Authorised 05/05/2026
Single-centre, randomised, double-blind, split-face comparative design clinical trial to evaluate the efficacy and safety of the topical formulation with 4% hydroquinone and 0,025% tretinoin versus the formulation with 4% hydroquinone in patients with facial melasma
facial melasma
Mesoestetic Pharma Group S.L. · 21 participants
📍 Spain
2025-521806-16-00 on CTIS ↗
Phase I Neoplasms Authorised 05/05/2026
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
Small Cell Lung Cancer
Amgen Inc. · 53 participants
📍 Spain · Germany · Poland · Belgium · France
2025-522888-15-00 on CTIS ↗
Phase IV Not possible to specify Authorised 05/05/2026
Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)
Infectious diseases
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 136 participants
📍 Spain
2025-524264-38-00 on CTIS ↗
Phase I/II Neoplasms Authorised 05/05/2026
PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)
HER2 positive advanced breast cancer
Medica Scientia Innovation Research S.L. · 129 participants
📍 Spain
2025-524613-89-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/05/2026
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Persistent Corneal Epithelial Defect (PCED)
Dompe' Farmaceutici S.p.A. · 91 participants
📍 Czechia · Italy · Netherlands · Poland · Germany · Spain · Hungary · France
2025-523443-35-00 on CTIS ↗
Phase II Immune System Diseases Authorised 05/05/2026
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Graves’ Disease
Immunovant Sciences GmbH · 128 participants
📍 Italy · Greece · Germany · Hungary · Poland · Czechia · Netherlands · Spain · Belgium · Bulgaria · Latvia
2025-524001-33-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes
Obesity
Kailera Therapeutics Inc. · 612 participants
📍 Bulgaria · Hungary · Spain · Germany · Czechia · Poland
2025-523486-17-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Janssen Cilag International · 271 participants
📍 Denmark · Hungary · Portugal · Italy · Norway · Greece · Slovakia · Czechia · France · Poland · Bulgaria · Germany · Spain · Romania · Finland
2025-523552-31-00 on CTIS ↗
Phase II Eye Diseases Authorised 04/05/2026
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
Geographic atrophy secondary to age-related macular degeneration
Novartis Pharma AG · 142 participants
📍 Bulgaria · Romania · Germany · Czechia · Spain · Poland · Italy · Hungary · France
2025-523704-77-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes
Obesity
Kailera Therapeutics Inc. · 626 participants
📍 Hungary · Poland · Bulgaria · Germany · Czechia · Spain
2025-523510-87-00 on CTIS ↗
Phase II Immune System Diseases Authorised 04/05/2026
Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)
Systemic lupus erythematosus
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 106 participants
📍 Bulgaria · Romania · Germany · Spain · Hungary · Poland · Croatia
2025-523488-39-00 on CTIS ↗
Phase IV Mental Disorders Authorised 04/05/2026
Efficacy and Safety of Daridorexant in Patients with Major Depressive Disorder (MDD) and Insomnia: Double-blind, randomized, controlled trial
Patients with major depressive episode and moderate to severe insomnia disorder
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL · 134 participants
📍 Spain
2025-524794-16-00 on CTIS ↗
Phase II Mental Disorders Authorised 04/05/2026
Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach
Major depressive disorder
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau · 60 participants
📍 Spain
2025-521690-14-00 on CTIS ↗
Phase III Immune System Diseases Authorised 04/05/2026
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
IgA nephropathy
Novartis Pharma AG · 69 participants
📍 Belgium · France · Czechia · Croatia · Greece · Germany · Italy · Spain
2024-519638-22-00 on CTIS ↗
Phase III Neoplasms Authorised 04/05/2026
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC · 311 participants
📍 Denmark · Spain · Netherlands · Germany · France · Czechia · Poland · Italy · Greece
2024-516993-31-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 04/05/2026
CD5CAR-NK cells for refractory invasive mold disease
refractory invasive mold disease
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer · 10 participants
📍 Spain
2025-524638-24-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 04/05/2026
Staphylococcus aureus Network Adaptive Platform trial (SNAP)
Staphylococcus aureus bacteraemia
Fundacion Para La Gestion De La Investigacion En Salud De Sevilla · 230 participants
📍 Spain
2025-521388-11-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 30/04/2026
Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics versus antibiotic treatment. ADIANA Trial.
Diverticular disease of the intestine,
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia · 282 participants
📍 Spain
2025-523121-17-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 30/04/2026
Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Sustained Remission: A Multicenter Randomized Controlled Trial (IDEA).
Ulcerative Colitis
Grupo Espanol De Trabajo En Enfermedad De Crohn y Colitis Ulcerosa · 304 participants
📍 Spain
2025-524675-23-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/04/2026
A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors
refractory hypotension in distributive shock
Paion Pharma GmbH · 143 participants
📍 Italy · Germany · France · Spain
2025-523750-14-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 30/04/2026
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.
Psoriatic arthritis​​
Merck Sharp & Dohme LLC · 49 participants
📍 Poland · Germany · Spain
2025-520997-21-00 on CTIS ↗
Phase III Neoplasms Authorised 30/04/2026
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed or Refractory Multiple Myeloma
AstraZeneca AB · 153 participants
📍 Norway · Poland · Spain · Germany · France · Italy
2025-523285-25-00 on CTIS ↗
Phase I Neoplasms Authorised 30/04/2026
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines I GmbH · 24 participants
📍 Spain
2025-524857-15-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/04/2026
Bioequivalence clinical trial of two formulations of canagliflozin
Healthy volunteers
Laboratorios Normon S.A. · 36 participants
📍 Spain
2026-525944-14-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/04/2026
Bioequivalence clinical trial of two formulations of loperamide.
Healthy volunteers
Laboratorios Normon S.A. · 40 participants
📍 Spain
2026-525278-20-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/04/2026
Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.
Healthy volunteers
Farmalider S.A. · 8 participants
📍 Spain
2026-525930-47-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 28/04/2026
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
Active Idiopathic Inflammatory Myopathy including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio Inc. · 13 participants
📍 Italy · Spain · Germany
2025-521145-24-01 on CTIS ↗
Phase III Mental Disorders Authorised 28/04/2026
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
Xenon Pharmaceuticals Inc. · 70 participants
📍 Bulgaria · Germany · France · Spain
2025-522872-10-00 on CTIS ↗
Phase I Neoplasms Authorised 28/04/2026
​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
Amgen Inc. · 77 participants
📍 Spain · France · Belgium
2025-524056-63-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 28/04/2026
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc. · 94 participants
📍 Spain · Poland · Italy · Belgium · Latvia · Denmark · Czechia · Germany · France · Netherlands · Portugal · Ireland · Greece
2024-520218-23-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations
Merck Sharp & Dohme LLC · 37 participants
📍 Czechia · Spain · Poland · Belgium · Finland · Germany · France · Netherlands · Hungary · Denmark
2025-524160-38-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases
F. Hoffmann-La Roche AG · 237 participants
📍 Belgium · France · Italy · Austria · Romania · Poland · Portugal · Czechia · Germany · Spain · Hungary
2025-524498-17-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1
Dyne Therapeutics Inc. · 72 participants
📍 Netherlands · Spain · Italy · Denmark · Germany · Belgium · France
2025-522957-20-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 28/04/2026
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
Obesity and T2D
Novo Nordisk A/S · 157 participants
📍 Slovakia · Austria · Spain · Romania · Portugal · Italy · Denmark · Belgium · Sweden · Poland · Netherlands · Croatia · Hungary · Bulgaria
2023-509176-42-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
Ovarian cancer
Merck Sharp & Dohme LLC · 349 participants
📍 Norway · Ireland · Spain · Greece · France · Poland · Denmark · Austria · Hungary · Belgium · Czechia · Finland · Germany · Italy · Sweden
2023-508047-40-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome
Epygenix Therapeutics Inc. · 98 participants
📍 Italy · Spain · Hungary · Romania · Czechia · Poland
2025-522552-20-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia
Agitation in Alzheimer's Disease Dementia
Exciva GmbH · 222 participants
📍 Italy · Slovakia · Spain · Poland · Czechia · Germany
2024-517388-22-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/04/2026
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)
Classical Homocystinuria
Travere Therapeutics Inc. · 22 participants
📍 Belgium · Ireland · Spain · Italy · Germany · France · Portugal · Poland
2023-504135-40-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/04/2026
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
Obesity
Novo Nordisk A/S · 325 participants
📍 Belgium · Germany · Bulgaria · France · Spain · Denmark · Italy · Netherlands
2025-523804-62-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 27/04/2026
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines Inc. · 98 participants
📍 France · Spain · Italy · Germany
2025-523495-23-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 27/04/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)
Cancer-Associated Thrombosis (CAT).
Regeneron Pharmaceuticals Inc. · 324 participants
📍 Belgium · Czechia · France · Romania · Germany · Poland · Bulgaria · Spain
2024-519298-21-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 27/04/2026
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A. · 103 participants
📍 Belgium · Germany · Italy · Czechia · Bulgaria · Netherlands · France · Portugal · Poland · Spain · Romania
2024-514246-37-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 27/04/2026
Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients with chronic venous insufficiency
Chronic Venous Insufficiency
VeriGraft AB · 60 participants
📍 Spain
2025-524103-69-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 27/04/2026
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
severely active ulcerative colitis (US) and CD (Crohn’s disease)
Eli Lilly & Co. · 16 participants
📍 Spain · Denmark · Germany · Italy · Poland
2025-522362-78-00 on CTIS ↗
Phase II Neoplasms Authorised 27/04/2026
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
AstraZeneca AB · 63 participants
📍 Italy · Austria · Spain · Ireland · Czechia · Poland
2024-518858-17-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 27/04/2026
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer
Extensive-Stage Small Cell Lung Cancer
Fortvita Biologics (USA) Inc. · 30 participants
📍 Poland · Denmark · Spain
2025-523972-21-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 27/04/2026
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome
​​Fragile X Syndrome​
Mirum Pharmaceuticals Inc. · 15 participants
📍 Spain
2025-523738-21-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/04/2026
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
Novartis Pharma AG · 21 participants
📍 Italy · Spain · Germany · Netherlands · France · Denmark · Czechia
2025-522019-40-00 on CTIS ↗
Phase I Not possible to specify Authorised 27/04/2026
A Study of GEN1106 in Participants with Solid Tumors
Metastatic or advanced malignant solid tumors
Genmab A/S · 50 participants
📍 Spain
2025-523760-21-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 24/04/2026
A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 12-Week Trial to Evaluate the Efficacy and Safety of Treatment with K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg
Hypercholesterolemia
Kowa Co. Ltd. · 40 participants
📍 Spain
2025-523739-20-00 on CTIS ↗
Phase I/II Neoplasms Authorised 24/04/2026
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies
Advanced malignancies
Pharma Mar S.A. · 36 participants
📍 Spain
2025-523774-16-00 on CTIS ↗
Phase II Neoplasms Authorised 24/04/2026
A randomized phase 2 trial of neoadjuvant pembrolizumab plus belzutifan with or without lenvatinib in patients with localized renal cell carcinoma. The moonlanding trial
Patients with localized renal cell carcinoma
Vall D Hebron Institute Of Oncology · 90 participants
📍 Spain
2024-519673-18-00 on CTIS ↗
Phase II Neoplasms Authorised 24/04/2026
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.
Cutaneous squamous cell carcinoma (ccSCC)
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL · 15 participants
📍 Spain
2025-524255-32-00 on CTIS ↗
Phase I Neoplasms Authorised 22/04/2026
Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms
Malignant B-cell neoplasms
Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre · 24 participants
📍 Spain
2025-524814-27-00 on CTIS ↗
Phase I/II Musculoskeletal and Neural Physiological Phenomena Authorised 22/04/2026
Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)
Spinal cord injury
Sinfatin S.L. · 8 participants
📍 Spain
2025-524279-22-00 on CTIS ↗
Phase II Immune System Diseases Authorised 22/04/2026
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Rheumatoid arthritis
AstraZeneca AB · 97 participants
📍 Hungary · Spain · Bulgaria · Germany · Poland
2025-522076-85-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/04/2026
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Advanced or unresectable Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb Services Unlimited Company · 47 participants
📍 Poland · Spain · Germany · France · Italy
2025-523602-33-00 on CTIS ↗
Phase I Immune System Diseases Authorised 22/04/2026
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)
Genentech Inc. · 17 participants
📍 Italy · Spain · France · Germany
2025-522904-26-00 on CTIS ↗
Phase III Not possible to specify Authorised 21/04/2026
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia
Chemotherapy induced thrombocytopenia
Jiangsu Hengrui Pharmaceuticals Co. Ltd. · 58 participants
📍 France · Romania · Poland · Spain · Bulgaria
2025-524209-34-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 21/04/2026
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharma AG · 138 participants
📍 Netherlands · Germany · Spain · Italy · France · Belgium
2025-523481-24-00 on CTIS ↗
Phase I/II Musculoskeletal Diseases Authorised 21/04/2026
A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
Diffuse cutaneous systemic sclerosis (dcSSc) Difficult to treat rheumatoid arthritis (D2TRA)
Quell Therapeutics Limited · 8 participants
📍 Spain · Germany
2025-523971-46-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 21/04/2026
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
Chronic Kidney Disease
Universitair Medisch Centrum Groningen · 95 participants
📍 Germany · Spain · Netherlands
2025-525068-13-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/04/2026
C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Pfizer Inc. · 50 participants
📍 Germany · Spain
2025-523524-53-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 21/04/2026
J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Obesity, Overweight
Eli Lilly & Co. · 286 participants
📍 Spain · Romania · Belgium · Czechia
2025-523659-73-00 on CTIS ↗
Phase II Hormonal diseases Authorised 21/04/2026
Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study
type 2 diabetes
Novo Nordisk A/S · 145 participants
📍 Spain · Hungary · Portugal · Poland · Slovakia · Croatia
2025-523260-20-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/04/2026
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
Institut De Recherches Internationales Servier IRIS · 105 participants
📍 France · Spain · Denmark · Italy
2025-523474-16-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH · 186 participants
📍 Netherlands · Poland · Italy · Germany · Spain · Romania · Czechia · France · Sweden
2025-524366-21-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 20/04/2026
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Homeostatic iron regulator gene-related hereditary hemochromatosis
CSL Behring LLC · 50 participants
📍 Austria · Poland · Spain · Germany · France · Ireland · Romania · Belgium · Italy · Czechia · Netherlands
2025-523793-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/04/2026
Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
colon carcinoma metastases
HepaRegeniX GmbH · 40 participants
📍 France · Spain · Germany
2025-523630-59-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 102 participants
📍 Spain · France · Belgium · Germany
2025-522913-45-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG · 18 participants
📍 Spain · Hungary · Czechia · France · Italy · Belgium
2024-520125-36-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
Locally advanced/metastatic urothelial carcinoma
Merck Sharp & Dohme LLC · 265 participants
📍 Netherlands · Greece · Italy · Germany · Spain · Belgium · Sweden · France
2024-520014-22-00 on CTIS ↗
Phase II Immune System Diseases Authorised 20/04/2026
An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.
Multiple Sclerosis
Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol · 14 participants
📍 Belgium · Spain
2025-522040-40-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 20/04/2026
C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)
Pfizer Inc. · 31 participants
📍 Italy · Germany · France · Spain · Sweden · Greece
2025-523660-21-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/04/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A., Prilenia Therapeutics B.V. · 420 participants
📍 Belgium · Netherlands · Poland · France · Germany · Ireland · Italy · Sweden · Spain
2025-524002-16-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
Eli Lilly & Co. · 197 participants
📍 Italy · Poland · Denmark · Czechia · France · Hungary · Germany · Netherlands · Spain
2025-522855-25-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 17/04/2026
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
MaaT PHARMA · 18 participants
📍 Netherlands · Italy · France · Spain
2025-524302-15-00 on CTIS ↗
Phase III Neoplasms Authorised 17/04/2026
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
Ovarian cancer
Incyte Corp. · 308 participants
📍 Ireland · Poland · France · Netherlands · Spain · Italy · Germany · Belgium
2025-522748-42-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 17/04/2026
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
HFpEF or HFmrEF and obesity
Novo Nordisk A/S · 1992 participants
📍 Denmark · Greece · Bulgaria · Italy · Netherlands · Spain · Poland · Czechia · Germany · France
2025-523717-29-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 17/04/2026
A Phase 1 Study of AIR-001 in Adults with AATD.
Alpha-1 Antitrypsin Deficiency
Airna Corp. · 19 participants
📍 Sweden · Ireland · Spain · Netherlands · Portugal · Germany
2025-523558-14-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 17/04/2026
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Myelodysplastic neoplasms/syndromes (MDS)
Takeda Development Center Americas Inc. · 114 participants
📍 France · Belgium · Germany · Italy · Bulgaria · Ireland · Lithuania · Norway · Romania · Hungary · Spain · Greece · Poland · Netherlands
2025-523544-12-00 on CTIS ↗
Phase II Not possible to specify Authorised 17/04/2026
Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin
Categoria 2, Patients with vegetable allergies due to sensitization to profilin and LTPs, and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP) has not been effective, were evaluated in a before-after study to assess changes in clinical reactivity to LTP (peach) and profilin (melon) and immunological changes after intervention with omalizumab.
Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud · 37 participants
📍 Spain
2025-524629-42-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/04/2026
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
Advanced HR+/HER- breast cancer
Novartis Pharma AG · 55 participants
📍 Italy · Germany · France · Czechia · Denmark · Spain
2025-521911-38-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 16/04/2026
A study to evaluate how well single and multiple doses of S072 are tolerated in healthy adult participants
Pain
Sea4us Biotecnologia E Recursos Marinhos S.A. · 64 participants
📍 Spain
2025-525039-15-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 16/04/2026
The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia
B-cell Acute Lymphoblastic Leukemia
Prinses Maxima Centrum voor Kinderoncologie B.V. · 35 participants
📍 Spain · Germany · Netherlands
2025-523096-34-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 16/04/2026
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
Obesity
Metsera Inc. · 919 participants
📍 Czechia · Bulgaria · Slovakia · Spain · Hungary · Germany · Romania · Poland
2025-523975-48-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/04/2026
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Aop Orphan Pharmaceuticals GmbH · 60 participants
📍 Spain
2025-523396-38-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 15/04/2026
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE
Hypochondroplasia
Qed Therapeutics Inc. · 22 participants
📍 Spain · Norway
2025-523509-13-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/spain (Accessed: 6 July 2026).

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker.